This Article Full Text Full Text (PDF) All Versions of this Article: 51/2/259    most recent HYPERTENSIONAHA.107.099028v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Walcher, D. Articles by Marx, N. Search for Related Content PubMed PubMed Citation Articles by Walcher, D. Articles by Marx, N. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Related Collections Pathophysiology Other Treatment Other Vascular biology

(Hypertension. 2008;51:259.)
© 2008 American Heart Association, Inc.

Original Articles

Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-

Daniel Walcher; Katharina Hess; Philipp Heinz; Kerstin Petscher; Dusica Vasic; Ulrich Kintscher; Markus Clemenz; Martin Hartge; Katrin Raps; Vinzenz Hombach; Nikolaus Marx

From the Department of Internal Medicine II-Cardiology (D.W., K.H., P.H., K.P., D.V., K.R., V.H., N.M.), University of Ulm, Ulm, Germany; and the Center for Cardiovascular Research (U.K., M.C., M.H.), Institute of Pharmacology and Toxicology, Charite-Universitatsmedizin Berlin, Berlin, Germany.

Correspondence to Nikolaus Marx, Department of Internal Medicine II-Cardiology, University of Ulm, Robert-Koch-Str 8, D-89081 Ulm, Germany. E-mail nikolaus.marx{at}uniklinik-ulm.de

Migration of CD4-positive lymphocytes into the vessel wall represents an important step in early atherogenesis. Telmisartan is an angiotensin type 1 receptor (AT1R) blocker with peroxisome proliferator-activated receptor (PPAR)-–activating properties. The present study examined the effect of telmisartan on CD4-positive cell migration and the role of PPAR in this context. CD4-positive lymphocytes express both the AT1R and PPAR. Stimulation of CD4-positive lymphocytes with stromal cell-derived factor (SDF)-1 leads to a 4.1±3.1-fold increase in cell migration. Pretreatment of cells with telmisartan reduces this effect in a concentration-dependent manner to a maximal 1.6±0.7-fold induction at 10 µmol/L of telmisartan (P<0.01 compared with SDF-1–treated cells; n=22). Three different PPAR activators, rosiglitazone, pioglitazone, and GW1929, had similar effects, whereas eprosartan, a non-PPAR–activating AT1R blocker, did not affect chemokine-induced lymphocyte migration. Telmisartan’s effect on CD4-positive lymphocyte migration was mediated through an early inhibition of chemokine-induced phosphatidylinositol 3-kinase activity. Downstream, telmisartan inhibited F-actin formation, as well as intercellular adhesion molecule-3 translocation. Transfection of CD4-positive lymphocytes with PPAR small interfering RNA abolished telmisartan’s effect on migration, whereas blockade of the AT1R had no such effect. Telmisartan inhibits chemokine-induced CD4-positive cell migration independent of the AT1R via PPAR. These data provide a novel mechanism to explain how telmisartan modulates lymphocyte activation by its PPAR-activating properties.

Key Words: telmisartan • PPAR • angiotensin type 1 receptor blocker • CD4-positive lymphocytes • migration